Clinical trials
HBV clinical trials
Below are recruiting hbv clinical trials, each written for real people, not researchers. We’re tracking 51 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07769827Recruiting
Peginterferon alfa-2b for advanced liver cancer with hepatitis B
This study tests a drug called peginterferon alfa-2b for people with advanced liver cancer that cannot be removed by surgery and who also have hepatitis B. The drug aims to boost the immune system to fight the cancer and may help control the disease.
Nanjing, JiangsuAges 18 years+ - NCT04942886Enrolling by invitation
Preventing hepatitis B reactivation after stem cell transplant
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
SeoulAges 19–70 - NCT04745403RecruitingPhase 1
Trial of redirected HBV-targeting T cells for liver cancer
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
SingaporeAges 21–75 - NCT06906016Recruiting
New blood tests for hepatitis B
This study looks at new blood tests (biomarkers) to better understand chronic hepatitis B and how it affects treatment decisions. It may help doctors find better ways to manage your condition.
Créteil, CréteilAges 18 years+ - NCT07137247Recruiting
How the immune system changes over time in chronic hepatitis B
This study tracks how the immune system works in people with chronic hepatitis B who haven't taken antiviral medication in the last 6 months. It aims to understand the natural history of the infection without treatment.
Guangzhou, GuangdongAges 1–80 - NCT07275554Recruiting
Gene patterns and risk prediction in hepatitis B liver failure
This study looks at how gene changes (methylation) in people with hepatitis B-related liver failure may predict how well they will do. It aims to create a risk score to guide treatment.
Jinan, ShandongAges 18 years+ - NCT07254208Enrolling by invitation
Long-term study for those who took PBGENE-HBV
This study follows people who have already received the experimental gene therapy PBGENE-HBV for hepatitis B. It aims to monitor long-term safety and health outcomes.
Boston, MassachusettsAges 19–80 - NCT06680232RecruitingPhase 1
Gene therapy trial for chronic hepatitis B
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Boston, MassachusettsAges 18–70 - NCT07160946Recruiting
Liver cancer risk check for people with hepatitis B
This study looks at your risk of developing liver cancer if you have hepatitis B. It uses your medical history and test results to give you a better idea of your risk and help guide next steps.
Guangzhou, GuangdongAges 30–75 - NCT07529171Recruiting
Monitoring hepatitis B reactivation in immunosuppressed patients
This study tracks patients who carry hepatitis B antibodies and are about to start immunosuppressive therapy (medications that weaken the immune system). Researchers want to understand when and how hepatitis B can reactivate in these patients and how to prevent it.
AdanaAges 18–80 - NCT06746701Recruiting
Peginterferon with NA to prevent liver cancer in hepatitis B
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
Guangzhou, GuangdongAges 18–65 - NCT06372990Recruiting
Quick T-cell test for hepatitis B and D
This study is testing a new blood test that quickly checks your T-cells (part of your immune system). It is for people with chronic hepatitis B or both hepatitis B and D.
Milan, MIAges 18 years+ - NCT03792919RecruitingPhase 4
Stopping long-term hepatitis B medicine vs continuing
This study compares outcomes for people with chronic hepatitis B who have long-term, stable viral suppression: stopping their antiviral medicine versus continuing it. It may help answer whether it’s safe to stop treatment in the right patients.
Hong Kong, Hong Kong SARAges Any age - NCT06047093Recruiting
Study of Hepatitis B Virus in the Liver
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
LyonAges 18 years+ - NCT06650852RecruitingPhase 2
A study of 3 drugs for chronic hepatitis B
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
Beijing, Beijing MunicipalityAges 18–60 - NCT06834178Recruiting
Counting undiagnosed hepatitis B, C and D in Austria
This study is looking for people in south-east Austria who have hepatitis B (HBV) or hepatitis C (HCV) that hasn't been fully treated or documented. It aims to find how many people also have hepatitis D (HDV) and are not yet aware of it.
Graz, StyraAges Any age - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT06961617RecruitingPhase 1
Immune cell therapy for advanced hepatitis B-related liver cancer
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
BeijingAges 18–70 - NCT07079150Recruiting
Long-term pegylated interferon study for HBV families with poor outcomes
This study looks at how well pegylated interferon alpha-2b works over the long term for people with chronic hepatitis B who come from families where the virus has caused serious liver problems like cirrhosis or liver cancer. The goal is to see if this treatment can help prevent these bad outcomes in family members.
Xi'an, ShaanxiAges 18–70 - NCT07170748Recruiting
Testing a new blood test for HIV, hepatitis B/C, and syphilis
This study evaluates a new blood test that checks for HIV, hepatitis B, hepatitis C, and syphilis all at once. It is designed to see how well the test works in different groups of people, including those with known infections and those without.
AbidjanAges 18 years+ - NCT07189377RecruitingPhase 4
Light, ex-vivo treatment and antivirals for lungs from hepatitis B donors
This trial tests a new way to safely use donor lungs that carry the hepatitis B virus (HBV). It combines a special light treatment, ex-vivo lung perfusion (cleaning the lungs outside the body), and antiviral medicines to prevent infection in the recipient. If you are on the lung transplant list and have been vaccinated against hepatitis B, this study may help expand your donor options.
Toronto, OntarioAges 18 years+ - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT06887036RecruitingPhase 2
Methylene blue for chronic inactive hepatitis B
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Lugano, Canton TicinoAges 18–79 - NCT07771140RecruitingPhase 1
Study of an experimental injection for chronic hepatitis b
Doctors are testing a new injectable treatment for chronic hepatitis B. This first-in-human study checks the drug's safety and how well it works in people who are already on standard hepatitis B pills.
HefeiAges 18–65
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hbv?
- Yes. Clin2 currently lists 51 recruiting hbv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hbv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hbv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.